Gapping up
In reaction to earnings/guidance:
- AOUT +9.8%, ACB +1.5% (guidance), DGX +1.3% (guidance), AEYE +1.1%
M&A news:
- TLRY +27.6% (Aphria (APHA) and Tilray (TLRY) combine to create largest global cannabis company)
- APHA +6.8% (Aphria (APHA) and Tilray (TLRY) combine to create largest global cannabis company)
- KNOP +3.1% (to acquire Tove Knutsen)
- OSK +2.7% (to acquire Pratt Miller)
- GDDY +1.4% (to acquire Poynt for $320 mln), IBM +0.1% (to acquire Expertus Technologies)
Other news:
- SIOX +41.5% (positive clinical data)
- NBSE +14.8% (announces positive preclinical in Vivo Data for PATrOL-enabled anti-gene for the treatment of myotonic dystrophy type 1)
- CLLS +12.9% (withdraws stock offering due to market condtions)
- EGLE +11% (announced that it has purchased a high-specification 2015-built SDARI-64 scrubber-fitted Ultramax bulkcarrier for a purchase price of $16 mln)
- VNTR +8.3% (discloses a plan to implement a restructuring program at certain of its manufacturing facilities in Germany as part of its recently announced 2020 Business Improvement Program)
- AUPH +4.5% (Aurinia Pharma and Lonza sign exclusive agreement for dedicated Voclosporin manufacturing capacity)
- VLDR +4.4% (announced a sales agreement for Alpha Prime sensors with May Mobility, a pioneer in autonomous vehicle technology )
- PGEN +4.2% (provides clinical developments at R&D Event)
- ARVN +3.7% (prices offering of 5,714,286 shares of its common stock at of $70.00 per share)
- BCRX +3.5% (announces USA availability of Orladeyo for the treatment of hereditary angioedema)
- NPA +3.2% (New Providence Acquisition: AST & Science to become public company through combination with New Providence Acquisition Corp)
- BNTX +2.6% (BioNTech and Fosun Pharma to supply China with mRNA-based COVID-19 Vaccine)
- KL +1.8% (increases quarterly dividend 50% to $0.1875/share)
- ACM +1.5% (has been selected to perform work through an Energy Savings Performance Contract for the Los Angeles County Water Pollution Control Plant)
- NVS +1.3% (receives positive FDA Advisory Committee recommendation for use of Entresto)
Analyst comments:
- TWTR +3.5% (upgraded to Overweight from Neutral at JP Morgan)
- AQUA +3.3% (upgraded to Outperform from Neutral at Robert W. Baird)
- HAIN +2% (upgraded to Overweight from Neutral at JP Morgan)
- ZNGA +2% (upgraded to Overweight from Neutral at JP Morgan)
- PANW +1.7% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)
- HPQ +1.6% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- MRO +1.4% (upgraded to Overweight from Equal Weight at Wells Fargo)
- NTAP +1.3% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- SQM +1.3% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- XOM +1.2% (upgraded to Buy from Neutral at Goldman)
- GE +1.1% (upgraded to Hold from Sell at DZ Bank)
- CMG +0.9% (upgraded to Buy from Hold at Stifel)
- XEC +0.9% (upgraded to Buy from Neutral at Goldman),